Anand Tandon, Market Expert told CNBC-TV18, "Glenmark Pharma for now looks like it is better positioned. Sun Pharma has some issues to tackle with regards to Ranbaxy Labs and as far as a technical position in the market is concerned as well. So if the choice is between the two I would take Glenmark."
Glenmark Pharma's trailing 12-month (TTM) EPS was at Rs 35.71 per share. (Mar, 2015). The stock's price-to-earnings (P/E) ratio was 23.36. The latest book value of the company is Rs 103.05 per share. At current value, the price-to-book value of the company was 8.09. The dividend yield of the company was 0.24 percent.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
